1 / 7

Opdyta 40mg injection | Apple pharmaceuticals

Opdyta 40mg is a prescription drug which is used under the supervision of a doctor, it belongs to a human monoclonal antibody which stops the interaction between PD-1 and its ligands, PD-L1 and PD-L2, it is an IgG4 kappa immunoglobulin which has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.

RoyceRobbie
Download Presentation

Opdyta 40mg injection | Apple pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Apple pharmaceuticals • Is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

  2. Nivolumab injection • Opdyta 40mg

  3. Opdyta 40mg is prescription drug which is used under supervision of doctor • Opdyta 40mg belongs to human monoclonal antibody which stops the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Opdyta 40mg is an IgG4 kappa immunoglobulin which has a calculated molecular mass of 146 kDa. • It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. • Opdyta 40mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. DESCRIPTION

  4. Opdyta 40mg is indicated for the treatment of patients having : • • Melanoma • • Non-Small Cell Lung Cancer • • Kidney (Renal Cell) Cancer INDICATION • MECHANISM • Binding of these ligands to the PD-1 receptor occur on T cells, prohibits T cell multiplication and cytokine production. Upregulation of the PD-1 ligands occurs in some tumor and signallingvia this pathway can provide to prohibition of active T-cell immune surveillance of tumor. Nivolumab belongs to human immunoglobulin G4 (IgG4) monoclonal antibody which binds to the PD-1 receptor and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated prevention of the immune response, containing the anti-tumor immune response, resulting in reduced tumor growth.

  5. Opdyta recommended dosage for unresectable or metastatic melanoma: • As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity • With ipilimumab: • The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment • For adjuvant treatment of melanoma: • As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year. • For Non-small cell lung cancer: • As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity. • For small cell lung cancer : • As single agent is either 240mg every 2 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year. DOSAGE

  6. PREGNANCY • There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a foetus. • LACTATION • Opdyta 40mg Excretion in human breast milk is not known; advise women to discontinue breastfeeding during treatment

  7. CALL: CONTACT US • +91-9987711567 • EMAIL ID: • applepharamaceutical@gmail.com • ADDRESS: Apartment No.304 A Wing, Shiva Shakthichs ltd, JP Road, Near ApnaBazar,Andheri(West),Mumbai - 400058.Maharashtra.

More Related